• STJ73562 Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0. 15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml) , showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
  • STJ73562 Flow cytometric analysis of paraformaldehyde fixed HeLa cells (blue line) , permeabilized with 0. 5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.

Anti-LIM domain only 3/lmo3 antibody (C-Term) (STJ73562)

SKU:
STJ73562-100

Shipping:
Free Shipping
Current Stock:
Host: Goat
Applications: Pep-ELISA/IF/IHC/FC
Reactivity: Human/Mouse/Dog/Pig
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Goat polyclonal antibody anti-LIM domain only 3/lmo3 (C-Term) is suitable for use in ELISA, Immunofluorescence, Immunohistochemistry and Flow Cytometry research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA
Purification: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Concentration: 0.5 mg/mL
Dilution Range: IF-Strong expression of the protein seen in the cytoplasm and nuclei of HeLa cells. 10µg/ml
ELISA-antibody detection limit dilution 1:128000.
Storage Instruction: Store at-20°C on receipt and minimise freeze-thaw cycles.
Gene Symbol: LMO3
Gene ID: 55885
Uniprot ID: LMO3_HUMAN
Immunogen Region: C-Term
Accession Number: NP_061110.2; NP_001230540.1; NP_001230541.1; NP_001230542.1
Immunogen Sequence: EGLMKEGYAPQVR
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance